# IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

> **NCT07441174** · PHASE1,PHASE2 · RECRUITING · sponsor: **InxMed (Shanghai) Co., Ltd.** · enrollment: 92 (estimated)

## Conditions studied

- Solid Tumor Cancer
- PDAC

## Interventions

- **DRUG:** IN10018 in combination with RNK08954

## Key facts

- **NCT ID:** NCT07441174
- **Lead sponsor:** InxMed (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2031-02-28
- **Final completion:** 2031-02-28
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441174, "IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07441174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*